gefitinib has been researched along with ci 988 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 147 | 8 | 14 |
| Protein | Taxonomy | gefitinib (IC50) | ci 988 (IC50) |
|---|---|---|---|
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 2.8672 | |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Cholecystokinin receptor type A | Homo sapiens (human) | 1.0471 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jensen, RT; Moody, TW; Moreno, P; Nuche-Berenguer, B | 1 |
1 other study(ies) available for gefitinib and ci 988
| Article | Year |
|---|---|
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dipeptides; ErbB Receptors; Gastrins; Gefitinib; Hormone Antagonists; Humans; Indoles; Lung Neoplasms; Meglumine; Pyrimidines; Quinazolines | 2015 |